Elsevier

Neurobiology of Disease

Volume 39, Issue 3, September 2010, Pages 352-361
Neurobiology of Disease

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

https://doi.org/10.1016/j.nbd.2010.05.001Get rights and content

Abstract

L-DOPA remains the gold-standard treatment for Parkinson's disease but causes motor fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for antidyskinetic therapies. Here, we evaluate the effects of fenobam, a noncompetitive mGluR5 antagonist already tested in humans, using rodent and nonhuman primate models of Parkinson's disease. In both animal models, acute administration of fenobam attenuated the L-DOPA-induced abnormal involuntary movements (50–70% reduction at the doses of 30 mg/kg in rats and 10 mg/kg in monkeys). The effect consisted in a reduction of peak-dose dyskinesia, whereas the end-dose phase was not affected. Chronic administration of fenobam to previously drug-naïve animals (de novo treatment) attenuated the development of peak-dose dyskinesia without compromising the anti-parkinsonian effect of L-DOPA. In addition, fenobam prolonged the motor stimulant effect of L-DOPA. We conclude that fenobam acts similarly in rat and primate models of L-DOPA-induced dyskinesia and represents a good candidate for antidyskinetic treatment in Parkinson's disease.

Introduction

The striatum is densely innervated by dopaminergic (DA) fibers from the substantia nigra and glutamatergic afferents from all parts of the cortex (Gerfen, 1992). Both dopamine (DA) and glutamate play major roles in the pathophysiology of Parkinson's disease (PD) (Calabresi et al., 2007, Chase and Oh, 2000). Loss of nigrostriatal DA fibers causes the main motor features of PD (Morrish et al., 1996) which can be pharmacologically treated with the DA precursor, L-DOPA. The medication remains the most effective treatment for PD but causes motor fluctuations and dyskinesia (abnormal involuntary movements) in up to 80% of the patients after a few years of treatment (Fabbrini et al., 2007). In both patients and animal models, L-DOPA-induced dyskinesia (LID) has been associated with plastic changes in pre-synaptic as well as post-synaptic neuronal targets in the striatum, including abnormal activation of key signaling kinases (Bezard et al., 2005, Picconi et al., 2003, Santini et al., 2007, Westin et al., 2007), elevated extracellular levels of glutamate (Robelet et al., 2004) and DA (Lindgren et al., 2010), and abnormal intracellular trafficking of DA and glutamate receptor subunits (Berthet and Bezard, 2009, Chase et al., 2000, Gardoni et al., 2006, Hallett et al., 2005, Silverdale et al., 2010). All these changes point to dysfunctional interactions between DA and glutamate neurotransmission in LID (Cenci and Lindgren, 2007, Cenci and Lundblad, 2006, Chase et al., 2000). Because antagonism of DA receptors may worsen PD motor symptoms, several glutamate receptor antagonists, especially of the ionotropic type, have been proposed for a pharmacological treatment of LID (Fox et al., 2006). Antagonists of ionotropic receptors may, however, induce cognitive and psychiatric impairments (Meldrum, 1998). Metabotropic glutamate receptors (mGluR) have received growing attention as potential targets for anti-parkinsonian and antidyskinetic treatments (Conn et al., 2005, Marino and Conn, 2006). Ligands to these receptors can normalize excessive glutamate transmission without blocking the physiological actions of glutamate in the brain (Rouse et al., 2000). Of particular interests is metabotropic glutamate receptor 5 (mGluR5), a G-protein coupled receptor that is positively linked to phosphoinositide hydrolysis (group I mGluRs) (Pin and Duvoisin, 1995). This receptor is highly expressed in striatal medium spiny neurons (Testa et al., 1994) where it plays a key role in modulating the responses mediated by NMDA receptors and L-type calcium channels (reviewed in Gubellini et al., 2004). We have previously shown that the selective mGluR5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP), can reduce the severity of LID and inhibit the associated molecular and neurochemical changes in rats with 6-hydroxydopamine (6-OHDA) lesions (Dekundy et al., 2006, Mela et al., 2007, Rylander et al., 2009). However, MTEP has no translational potential. We therefore searched for another mGluR5 antagonist, amenable to clinical use, in order to conduct a comprehensive preclinical validation of the mGluR5 target. Fenobam was under development already in the 1970s as non-benzodiazepine anxiolytic compound with potentially good safety profile (Pecknold et al., 1982) but was first identified as a potent, non-competitive mGluR5 antagonist in 2005 (Porter et al., 2005). It shares the same allosteric modulatory site as the prototypical mGluR5 antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP) (Gasparini et al., 1999) and, similar to MPEP, it is a candidate compound for the treatment of fragile X syndrome as well as pain (Berry-Kravis et al., 2009, Jacob et al., 2009, Montana et al., 2009). This study provides evidence of anti-dyskinetic and anti-akinetic effects of fenobam in two well-established animal models of PD. With its favourable profile of motor effects and its amenability to clinical use, fenobam can be regarded as a candidate treatment for motor complications in PD.

Section snippets

Animals

For the rat experiments, female Sprague–Dawley rats (Harlan, Netherlands), weighing 225–250 g at the beginning of the study were used. They were house in a 12 h dark–light cycle and had food and water ad libitum. All the procedures were approved by the Malmö-Lund ethical committee on animal research.

Non-human primate models of PD and LID were produced in male rhesus monkeys (Macaca mulatta, Xierxin, Beijing, PR of China; mean weight = 5.3 ± 0.8 kg; mean age = 5 ± 1 years) as in (Aubert et al., 2005).

Fenobam reduces already established LID and prolongs the effect of L-DOPA in the rat

In severely dyskinetic rats (n = 14), both doses of fenobam (30 mg/kg and 100 mg/kg) reduced the axial, limb, and orolingual AIM scores by approximately 50% up to 80 min following the administration of L-DOPA, corresponding to the beginning and the peak of the LID curve (Fig. 1A, repeated measures ANOVA, group effect: F(2,351) = 0.941, p = 0.398; time effect: F(9,351) = 46.318, p < 0.001; interaction: F(18,351) = 4.257, p < 0.001 and B, one-factor ANOVA, treatment effect: F(13,26) = 14.84, p < 0.001). When

Discussion

An overactive glutamate transmission plays an important role in PD, contributing both to the degeneration of DA neurons and to maladaptive plasticity and altered synaptic transmission in dopaminoceptive structures (for review see: Bezard et al., 2001a, Cenci and Lindgren, 2007; Chase et al., 2000, Fox et al., 2008, Miller et al., 1995).

Metabotropic glutamate receptor 5 is highly expressed post-synaptically on striatal medium spiny neurons and interneurons (Testa et al., 1994) where it plays a

Acknowledgments

This study was supported by grants from the Michael J. Fox Foundation for Parkinson's Research (MAC and EB), and from the Swedish National Research Council and European Community [Contract 222918] (MAC).

References (70)

  • A. Dekundy et al.

    Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease

    Brain Res. Bull.

    (2006)
  • S.H. Fox et al.

    Non-dopaminergic treatments in development for Parkinson's disease

    Lancet Neurol.

    (2008)
  • F. Gasparini et al.

    2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist

    Neuropharmacology

    (1999)
  • P. Gubellini et al.

    Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases

    Prog. Neurobiol.

    (2004)
  • P.J. Hallett et al.

    Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

    Neuropharmacology

    (2005)
  • W. Jacob et al.

    The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning

    Neuropharmacology

    (2009)
  • C. Konradi et al.

    Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia

    Neurobiol. Dis.

    (2004)
  • G. Levandis et al.

    Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

    Neurobiol. Dis.

    (2008)
  • W. Loscher et al.

    mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy

    Neuropharmacology

    (2006)
  • P. Mares

    Age-dependent anticonvulsant action of antagonists of group I glutamate metabotropic receptors in rats

    Epilepsy Res.

    (2009)
  • M.J. Marino et al.

    Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors

    Curr. Opin. Pharmacol.

    (2006)
  • B.S. Meldrum

    The glutamate synapse as a therapeutical target: perspectives for the future

    Prog. Brain Res.

    (1998)
  • N. Morin et al.

    Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

    Neuropharmacology

    (2010)
  • A. Nadjar et al.

    Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

    Prog. Neurobiol.

    (2009)
  • J.P. Pin et al.

    The metabotropic glutamate receptors: structure and functions

    Neuropharmacology

    (1995)
  • A. Pisani et al.

    Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons

    Neuroscience

    (2001)
  • S.T. Rouse et al.

    Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders

    Pharmacol. Ther.

    (2000)
  • P. Samadi et al.

    Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias

    Neuropharmacology

    (2008)
  • W.P. Spooren et al.

    Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats

    Eur. J. Pharmacol.

    (2000)
  • J.E. Westin et al.

    Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors

    Biol. Psychiatry

    (2007)
  • N. Yamamoto et al.

    Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

    Neuroscience

    (2009)
  • I. Aubert et al.

    Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia

    Ann. Neurol.

    (2005)
  • E. Berry-Kravis et al.

    A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

    J. Med. Genet.

    (2009)
  • E. Bezard et al.

    Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

    Nat. Rev. Neurosci.

    (2001)
  • E. Bezard et al.

    Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

    J. Neurosci.

    (2001)
  • Cited by (0)

    1

    Shared senior authorship.

    View full text